Cardinal (CAH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks
01 May

For the quarter ended March 2025, Cardinal Health (CAH) reported revenue of $54.88 billion, down 0.1% over the same period last year. EPS came in at $2.35, compared to $2.08 in the year-ago quarter.

The reported revenue represents a surprise of -0.27% over the Zacks Consensus Estimate of $55.03 billion. With the consensus EPS estimate being $2.15, the EPS surprise was +9.30%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Cardinal performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- Pharmaceutical and Specialty Solutions: $50.43 billion versus the four-analyst average estimate of $50.33 billion. The reported number represents a year-over-year change of -0.4%.
  • Revenue- Other: $1.30 billion versus $1.29 billion estimated by four analysts on average.
  • Revenue- Medical Products and Distribution: $3.16 billion versus the four-analyst average estimate of $3.21 billion. The reported number represents a year-over-year change of +1.5%.
  • Segment profit- Pharmaceutical and Specialty Solutions: $662 million versus $635.77 million estimated by four analysts on average.
  • Segment profit- Other: $134 million versus $119.24 million estimated by four analysts on average.
  • Segment profit- Global Medical Products and Distribution: $39 million compared to the $44.16 million average estimate based on four analysts.
View all Key Company Metrics for Cardinal here>>>

Shares of Cardinal have returned +1.9% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Cardinal Health, Inc. (CAH) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10